Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
2011
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study
2012
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
2009
Cancer statistics, 2022
2022 Standout
Membrane curvature regulates the spatial distribution of bulky glycoproteins
2022 StandoutNobel
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
2014
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
2013
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
2015
Antitumor activity of HER-2 inhibitors
2004
Immunotherapy of cancer in 2012
2012
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
2015
Cancer Statistics, 2021
2021 Standout
The emerging role of computerized tomography in assessing cancer cachexia
2009
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Pathogen recognition and development of particulate vaccines: Does size matter?
2006
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Therapeutic cancer vaccines: are we there yet?
2010
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
Lung Cancer
2008 Standout
Cancer cachexia: Developing multimodal therapy for a multidimensional problem
2008
ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II study
2003
Lung cancer: New biological insights and recent therapeutic advances
2011
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
2010
Lung cancer: current therapies and new targeted treatments
2016 Standout
Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes
2010
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
MUC1: a multifaceted oncoprotein with a key role in cancer progression
2014
Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
2015
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis
2015
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Mucins in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Implications
2014
Stimulated Release of Size‐Selected Cargos in Succession from Mesoporous Silica Nanoparticles
2012 StandoutNobel
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Revealing the human mucinome
2022 StandoutNobel
Drug discovery for a new generation of covalent drugs
2012
Cancer-associated mucins: role in immune modulation and metastasis
2019
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Capecitabine: A review
2005
Monoclonal antibodies as therapeutic agents for cancer
2004
Current state of immunotherapy for non-small cell lung cancer
2007
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells
2011
Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis
2015
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
2011
Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
2010
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Cancer Immunology
2008
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
2006 Standout
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
2008 Standout
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
2010
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care
2008 Standout
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
2021
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
2008
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
2015
Current Data with Pemetrexed in Non–Small-Cell Lung Cancer
2003
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines
2006
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
2015
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
2005
Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data
2011
Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment
2006
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer
2006
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Polydopamine and Its Derivative Materials: Synthesis and Promising Applications in Energy, Environmental, and Biomedical Fields
2014 Standout
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
2007
Chimeric Antigen Receptor Therapy
2018 Standout
New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
2014
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
2017
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
2010
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Therapeutic cancer vaccines
2015
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
2012
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.
2015
Works of Charles Butts being referenced
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
2007
Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
2003
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
2009
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
2019
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
2008
The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy
1998
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
2011
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
2013
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
2005
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.
2013
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets.
2016
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
2004
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity
2007
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
2009
A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10
2004
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
1999
Thymidylate synthase and thymidine phosphorylase expression in resected colorectal liver metastases do not predict overall survival nor response to chemotherapy
2004
A phase II study of neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for resectable liver metastases from colorectal cancer
2005
L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
2007
Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)
2007
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20
2007